Researchers at the Johns Hopkins University School of Medicine say that psilocybin should be moved from Schedule I to Schedule IV based on the 8 factors in the US Controlled Substances Act (CSA). Their recommendation is contingent upon the successful completion of phase III clinical trials with psilocybin. In the article, the Hopkins researchers discuss the current knowledge base on psilocybin and point out current promising research on its use in treating depression and anxiety in patients dealing with life-threatening cancer diagnoses, treatment-resistant depression, alcoholism, and tobacco addiction. “…the data suggest that the potential therapeutic benefits of psilocybin-assisted therapy are real, and of potential medical and public health significance.”